A Phase 2 Urinary Biomarker Study of Polyamine Inhibition With Sulindac and Difluoromethylornithine (DFMO)

Trial Profile

A Phase 2 Urinary Biomarker Study of Polyamine Inhibition With Sulindac and Difluoromethylornithine (DFMO)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2014

At a glance

  • Drugs Eflornithine (Primary) ; Sulindac (Primary)
  • Indications Cancer; Pain; Rheumatic disorders
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 30 May 2013 Planned End Date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov.
    • 30 May 2013 Planned initiation date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 17 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top